An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Lilly’s Retatrutide Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial On May 21, Eli Lilly and Company , the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes.
At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) met the primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss. “Obesity is a chronic disease, and people living with obesity deserve treatment options that match the complex biology of their neurometabolic disease,” said Ania Jastreboff, MD, PhD, professor of medicine and pediatrics (endocrinology) at the Yale School of Medicine, director of the Yale Obesity Research Center (Y-Weight), and lead investigator.
Endocrine News published a clinical update in Research Highlights on 22 May 2026.
The item focuses on Pharma Friday – May 22, 2026.
Review the original article for the full source wording and details.